Document is current
Any future updates will be listed below
-
Authors
Sivapalan, Lavanya
Murray, Joseph C
Canzoniero, Jenna VanLiere
Landon, Blair
Jackson, Jennifer
Scott, Susan
Lam, Vincent
Levy, Benjamin P.
Sausen, Mark
Anagnostou, Valsamo https://orcid.org/0000-0001-9480-3047
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01903993 at ClinicalTrials.govnct02008227 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
https://doi.org/10.1136/bmjonc-2023-000128
435 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0435
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(16)00587-0
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
https://doi.org/10.1136/jitc-2024-010578
26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
https://doi.org/10.1136/jitc-2021-sitc2021.026
46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
https://doi.org/10.1136/jitc-2023-sitc2023.0046
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
https://doi.org/10.1136/jitc-2023-006913
329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials
https://doi.org/10.1136/jitc-2021-sitc2021.329
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
https://doi.org/10.1200/jco.2024.42.16_suppl.2607
831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research
https://doi.org/10.1136/jitc-2021-sitc2021.831
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
https://doi.org/10.1136/jitc-2019-000500
nct02453282 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
https://doi.org/10.1136/bmjonc-2023-000128
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0584
435 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0435
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(16)00587-0
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
https://doi.org/10.1136/jitc-2024-010578
26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
https://doi.org/10.1136/jitc-2021-sitc2021.026
46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
https://doi.org/10.1136/jitc-2023-sitc2023.0046
Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC
https://doi.org/10.1136/jitc-2025-013098
28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology
https://doi.org/10.1136/jitc-2021-sitc2021.028
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
1090 Cross-cancer immunotherapy response prediction with the CURE AI foundation model
https://doi.org/10.1136/jitc-2025-sitc2025.1090
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
https://doi.org/10.1136/jitc-2023-006913
329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials
https://doi.org/10.1136/jitc-2021-sitc2021.329
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
https://doi.org/10.1200/jco.2024.42.16_suppl.2607
831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research
https://doi.org/10.1136/jitc-2021-sitc2021.831
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
https://doi.org/10.1136/jitc-2019-000500
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
https://doi.org/10.1136/jitc-2020-001882
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231
nct02542293 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients
https://doi.org/10.1136/jitc-2022-sitc2022.0583
605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
https://doi.org/10.1136/jitc-2023-sitc2023.0605
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
nct02848651 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
nct03178552 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
nct03668119 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
https://doi.org/10.1136/bmjopen-2021-060342
Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan
https://doi.org/10.1200/po.23.00314
nct02450331 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
https://doi.org/10.1136/jitc-2023-007339
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
https://doi.org/10.1136/jitc-2024-008872
nct04385368 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy
https://doi.org/10.1136/jitc-2023-008040
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
https://doi.org/10.1136/jitc-2019-000162
Advances in diagnosis and treatment of bladder cancer
https://doi.org/10.1136/bmj-2023-076743
445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010
https://doi.org/10.1136/jitc-2023-sitc2023.0445
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Regulatory implications of ctDNA in immuno-oncology for solid tumors
https://doi.org/10.1136/jitc-2022-005344
nct04642469 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies
https://doi.org/10.1136/jitc-2025-014098
nct04585490 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies
https://doi.org/10.1136/jitc-2025-014098
nct04849364 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
nct04138628 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
nct03808441 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
nct04093167 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
nct04166487 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Next-generation ctDNA-driven clinical trials in precision immuno-oncology
https://doi.org/10.1136/jitc-2022-006397
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps8669
nct04093167 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2020-001504
nct04166487 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Next-generation ctDNA-driven clinical trials in precision immuno-oncology
https://doi.org/10.1136/jitc-2022-006397
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps8669
nct04966676 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2020-001504
Documents that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Next-generation ctDNA-driven clinical trials in precision immuno-oncology
https://doi.org/10.1136/jitc-2022-006397
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (CA190755)
International Lung Cancer Foundation (N/A)
Emerson Collective (N/A)
National Institutes of Health (CA121113)
- License Information
